Xiao Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiao Zhang has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Xiaoli Lan
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
23 shared publications - Yongkang Gai
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
17 shared publications - Weiwei Ruan
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
13 shared publications - Xiangming Song
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
11 shared publications - Yuan Feng
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan 430022, China
11 shared publications - Danzha Zheng
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
10 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Comparison of [18F]PFPN and [18F]FDG PET in Mucosal Melanoma: Diagnostic Performance, Staging Impact, and Correlation with Molecular Markers
Purpose:The study aims to compare the diagnostic performance of the novel melanin-targeted [18F]-N-(2-(diethylamino)ethyl)-5-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)picolinamide ([18F]PFPN) positron emission tomography (PET) and [18F]fluorodeoxyglucose ([18F]FDG) PET in mucosal melanoma, evaluate their impact on clinical staging, and assess correlations between imaging metrics and molecular markers.Experimental Design:This prospective study enrolled 65 participants with histologically confirmed mucosal melanoma from February 2021 to January 2025. All participants underwent both [18F]FDG PET and [18F]PFPN PET within 1 week. Lesion- and participant-based analyses compared detection sensitivity, false-positive rate, and staging concordance. Quantitative PET parameters were analyzed, and correlations with HMB45, SOX10, MelanA, S100, and mutation status (BRAF, KIT, NRAS) were evaluated using nonparametric tests and correlation analysis with Bonferroni correction. Decision curve analysis was used to evaluate clinical benefit.Results:Sixty-five participants were included. [18F]PFPN PET showed higher lesion-based sensitivity than [18F]FDG PET [363/399 (91%) vs. 332/399 (83.2%)] and no false positives [0/363 (0%) vs. 4/336 (1.2%)]. The normalized maximum standardized uptake value was significantly higher for [18F]PFPN across all lesion types (P < 0.05). PFPN-based staging was more consistent with clinical staging (6.2% vs. 18.5% discordant cases). [18F]PFPN uptake showed significant positive correlations with HMB45 and SOX10 expression, whereas [18F]FDG parameters showed no such associations.Conclusions:[18F]PFPN PET outperforms [18F]FDG PET in lesion detection and clinical staging in mucosal melanoma, especially for liver and bone metastases. Its association with melanin differentiation markers may support its use in personalized imaging strategies.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Comparison of [18F]PFPN and [18F]FDG PET in Mucosal Melanoma: Diagnostic Performance, Staging Impact, and Correlation with Molecular Markers
Purpose:The study aims to compare the diagnostic performance of the novel melanin-targeted [18F]-N-(2-(diethylamino)ethyl)-5-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)picolinamide ([18F]PFPN) positron emission tomography (PET) and [18F]fluorodeoxyglucose ([18F]FDG) PET in mucosal melanoma, evaluate their impact on clinical staging, and assess correlations between imaging metrics and molecular markers.Experimental Design:This prospective study enrolled 65 participants with histologically confirmed mucosal melanoma from February 2021 to January 2025. All participants underwent both [18F]FDG PET and [18F]PFPN PET within 1 week. Lesion- and participant-based analyses compared detection sensitivity, false-positive rate, and staging concordance. Quantitative PET parameters were analyzed, and correlations with HMB45, SOX10, MelanA, S100, and mutation status (BRAF, KIT, NRAS) were evaluated using nonparametric tests and correlation analysis with Bonferroni correction. Decision curve analysis was used to evaluate clinical benefit.Results:Sixty-five participants were included. [18F]PFPN PET showed higher lesion-based sensitivity than [18F]FDG PET [363/399 (91%) vs. 332/399 (83.2%)] and no false positives [0/363 (0%) vs. 4/336 (1.2%)]. The normalized maximum standardized uptake value was significantly higher for [18F]PFPN across all lesion types (P < 0.05). PFPN-based staging was more consistent with clinical staging (6.2% vs. 18.5% discordant cases). [18F]PFPN uptake showed significant positive correlations with HMB45 and SOX10 expression, whereas [18F]FDG parameters showed no such associations.Conclusions:[18F]PFPN PET outperforms [18F]FDG PET in lesion detection and clinical staging in mucosal melanoma, especially for liver and bone metastases. Its association with melanin differentiation markers may support its use in personalized imaging strategies.
- Open Access
- 9 April 2026
- Published by Elsevier in The EANM Journal
- Vol. 3
[68Ga]Ga-GZP and [18F]FDG PET for early response prediction in locally advanced rectal cancer undergoing neoadjuvant immunochemoradiotherapy
- 9 April 2026
- Published by Elsevier in The EANM Journal
- Vol. 3
Open Access[68Ga]Ga-GZP and [18F]FDG PET for early response prediction in locally advanced rectal cancer undergoing neoadjuvant immunochemoradiotherapy
- 4 March 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (10) , 2036-2046
Comparison of [18F]PFPN and [18F]FDG PET in Mucosal Melanoma: Diagnostic Performance, Staging Impact, and Correlation with Molecular Markers
Purpose: The study aims to compare the diagnostic performance of the novel melanin-targeted [18F]-N-(2-(diethylamino)ethyl)-5-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)picolinamide ([18F]PFPN) positron emission tomography (PET) and [18F]fluorodeoxyglucose ([18F]FDG) PET in mucosal melanoma, evaluate their impact on clinical staging, and assess correlations between imaging metrics and molecular markers. Experimental Design: This prospective study enrolled 65 participants with histologically confirmed mucosal melanoma from February 2021 to January 2025. All participants underwent both [18F]FDG PET and [18F]PFPN PET within 1 week. Lesion- and participant-based analyses compared detection sensitivity, false-positive rate, and staging concordance. Quantitative PET parameters were analyzed, and correlations with HMB45, SOX10, MelanA, S100, and mutation status (BRAF, KIT, NRAS) were evaluated using nonparametric tests and correlation analysis with Bonferroni correction. Decision curve analysis was used to evaluate clinical benefit. Results: Sixty-five participants were included. [18F]PFPN PET showed higher lesion-based sensitivity than [18F]FDG PET [363/399 (91%) vs. 332/399 (83.2%)] and no false positives [0/363 (0%) vs. 4/336 (1.2%)]. The normalized maximum standardized uptake value was significantly higher for [18F]PFPN across all lesion types (P < 0.05). PFPN-based staging was more consistent with clinical staging (6.2% vs. 18.5% discordant cases). [18F]PFPN uptake showed significant positive correlations with HMB45 and SOX10 expression, whereas [18F]FDG parameters showed no such associations. Conclusions: [18F]PFPN PET outperforms [18F]FDG PET in lesion detection and clinical staging in mucosal melanoma, especially for liver and bone metastases. Its association with melanin differentiation markers may support its use in personalized imaging strategies.
- 4 March 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (10) , 2036-2046
Comparison of [18F]PFPN and [18F]FDG PET in Mucosal Melanoma: Diagnostic Performance, Staging Impact, and Correlation with Molecular Markers
Purpose: The study aims to compare the diagnostic performance of the novel melanin-targeted [18F]-N-(2-(diethylamino)ethyl)-5-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)picolinamide ([18F]PFPN) positron emission tomography (PET) and [18F]fluorodeoxyglucose ([18F]FDG) PET in mucosal melanoma, evaluate their impact on clinical staging, and assess correlations between imaging metrics and molecular markers. Experimental Design: This prospective study enrolled 65 participants with histologically confirmed mucosal melanoma from February 2021 to January 2025. All participants underwent both [18F]FDG PET and [18F]PFPN PET within 1 week. Lesion- and participant-based analyses compared detection sensitivity, false-positive rate, and staging concordance. Quantitative PET parameters were analyzed, and correlations with HMB45, SOX10, MelanA, S100, and mutation status (BRAF, KIT, NRAS) were evaluated using nonparametric tests and correlation analysis with Bonferroni correction. Decision curve analysis was used to evaluate clinical benefit. Results: Sixty-five participants were included. [18F]PFPN PET showed higher lesion-based sensitivity than [18F]FDG PET [363/399 (91%) vs. 332/399 (83.2%)] and no false positives [0/363 (0%) vs. 4/336 (1.2%)]. The normalized maximum standardized uptake value was significantly higher for [18F]PFPN across all lesion types (P < 0.05). PFPN-based staging was more consistent with clinical staging (6.2% vs. 18.5% discordant cases). [18F]PFPN uptake showed significant positive correlations with HMB45 and SOX10 expression, whereas [18F]FDG parameters showed no such associations. Conclusions: [18F]PFPN PET outperforms [18F]FDG PET in lesion detection and clinical staging in mucosal melanoma, especially for liver and bone metastases. Its association with melanin differentiation markers may support its use in personalized imaging strategies.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Glypican-3–Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside
Supplementary Figure S1. Summary of study design and imaging workflow.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Glypican-3–Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside
Supplementary Figure S1. Summary of study design and imaging workflow.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Data from Glypican-3–Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside
Purpose:This study aims to develop and evaluate a novel glypican-3 (GPC3)–targeted, single-chain variable fragment–based PET radiotracer for noninvasive assessment of GPC3 expression and precise diagnosis of hepatocellular carcinoma (HCC) in both preclinical models and a first-in-human clinical study.Experimental Design:The novel anti-GPC3 single-chain variable fragment, namely, XH-06, was labeled with gallium-68 to obtain [68Ga]Ga-XH-06. Cell uptake assays, small-animal PET imaging, and biodistribution studies were performed to evaluate its targeting ability. In the first-in-human study, eight patients with suspected HCC underwent [68Ga]Ga-XH-06 PET/MRI. Radiotracer uptake in tumors and normal tissues was quantified, and tumor-to-blood ratios and tumor-to-liver ratios were calculated.Results:[68Ga]Ga-XH-06 was synthesized with high radiochemical purity and exhibited specific uptake and efficient internalization in GPC3-positive cells. In subcutaneous and orthotopic animal models, [68Ga]Ga-XH-06 effectively visualized HCC tumors. Eight patients underwent [68Ga]Ga-XH-06 PET/MRI scans, and no adverse events were observed. The radiotracer successfully detected HCC lesions, including subcentimeter tumors, with high imaging contrast. Among seven patients with HCC, the median maximum standardized uptake value of the lesions was 16.9 (range, 8.2–51.8), the median tumor-to-liver ratio was 6.2 (range, 2.8–24.7), and the median tumor-to-blood ratio was 16.6 (range, 3.0–57.6) at 2.5 hours after injection.Conclusions:[68Ga]Ga-XH-06 is clinically promising for detecting GPC3-positive HCC with a favorable safety profile. Further investigation is warranted to validate the clinical value of GPC3-targeted PET imaging in HCC management.See related commentary by Seo and Flavell, p. 445
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Glypican-3–Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside
Purpose:This study aims to develop and evaluate a novel glypican-3 (GPC3)–targeted, single-chain variable fragment–based PET radiotracer for noninvasive assessment of GPC3 expression and precise diagnosis of hepatocellular carcinoma (HCC) in both preclinical models and a first-in-human clinical study.Experimental Design:The novel anti-GPC3 single-chain variable fragment, namely, XH-06, was labeled with gallium-68 to obtain [68Ga]Ga-XH-06. Cell uptake assays, small-animal PET imaging, and biodistribution studies were performed to evaluate its targeting ability. In the first-in-human study, eight patients with suspected HCC underwent [68Ga]Ga-XH-06 PET/MRI. Radiotracer uptake in tumors and normal tissues was quantified, and tumor-to-blood ratios and tumor-to-liver ratios were calculated.Results:[68Ga]Ga-XH-06 was synthesized with high radiochemical purity and exhibited specific uptake and efficient internalization in GPC3-positive cells. In subcutaneous and orthotopic animal models, [68Ga]Ga-XH-06 effectively visualized HCC tumors. Eight patients underwent [68Ga]Ga-XH-06 PET/MRI scans, and no adverse events were observed. The radiotracer successfully detected HCC lesions, including subcentimeter tumors, with high imaging contrast. Among seven patients with HCC, the median maximum standardized uptake value of the lesions was 16.9 (range, 8.2–51.8), the median tumor-to-liver ratio was 6.2 (range, 2.8–24.7), and the median tumor-to-blood ratio was 16.6 (range, 3.0–57.6) at 2.5 hours after injection.Conclusions:[68Ga]Ga-XH-06 is clinically promising for detecting GPC3-positive HCC with a favorable safety profile. Further investigation is warranted to validate the clinical value of GPC3-targeted PET imaging in HCC management.See related commentary by Seo and Flavell, p. 445
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Glypican-3–Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside
Supplementary Figure S6. Quantitative ROI data in [68Ga]Ga-XH-06 immunoPET imaging of Hep3B orthotopic xenograft models.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Glypican-3–Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside
Supplementary Figure S6. Quantitative ROI data in [68Ga]Ga-XH-06 immunoPET imaging of Hep3B orthotopic xenograft models.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Glypican-3–Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside
Supplementary Table S1. Kinetic parameters of the interaction between anti-GPC3 scFv (XH-06) and NOTA-XH-06 with human GPC3 protein determined by biolayer interferometry.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Glypican-3–Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside
Supplementary Table S1. Kinetic parameters of the interaction between anti-GPC3 scFv (XH-06) and NOTA-XH-06 with human GPC3 protein determined by biolayer interferometry.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Glypican-3–Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside
Supplementary Figure S2. Sample purity determination using size exclusion-high-performance liquid chromatography. The purity of anti-GPC3 scFv (XH-06) was 100%.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Glypican-3–Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside
Supplementary Figure S2. Sample purity determination using size exclusion-high-performance liquid chromatography. The purity of anti-GPC3 scFv (XH-06) was 100%.